Overview

Assessment of Quizartinib Pharmacokinetic in Subjects With Severe Hepatic Impairment

Status:
RECRUITING
Trial end date:
2025-06-30
Target enrollment:
Participant gender:
Summary
This study will evaluate and compare the PK in subjects with severe HI to that of matched healthy control subjects with normal hepatic function.
Phase:
PHASE1
Details
Lead Sponsor:
Daiichi Sankyo
Treatments:
quizartinib